Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study.

Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study.

BACKGROUND: Low-density lipoprotein (LDL) cholesterol and high-density lipoprotein (HDL) cholesterol are established risk factors for vascular disease, but lipoprotein particle concentrations may be stronger determinants of risk. METHODS AND RESULTS: Associations between vascular events and baseline...

Bibliografski detalji
Glavni autori:	Parish, S, Offer, A, Clarke, R, Hopewell, J, Hill, MR, Otvos, J, Armitage, J, Collins, R
Format:	Journal article
Jezik:	English
Izdano:	2012

Slični predmeti

MRC/BHF Heart Protection Study - Reply
od: Collins, R, i dr.
Izdano: (2002)

Comments on the MRC/BHF Heart Protection Study - Authors' reply
od: Collins, R, i dr.
Izdano: (2003)

The MRC/BHF Heart Protection Study: preliminary results.
od: Collins, R, i dr.
Izdano: (2002)

N-BNP and vascular disease among 20,536 patients in the MRC/BHF Heart Protection Study
od: Emberson, J, i dr.
Izdano: (2005)

MRC/BHF heart protection study (HPS): Mortality, cancer incidence and major vascular events during 4 years post-trial follow-up of HPS
od: Bulbulia, R, i dr.
Izdano: (2007)

MRC/BHF Heart Protection Study.
od: Vaughan, C, i dr.
Izdano: (2002)

N-terminal pro-B-type natriuretic peptide and vascular disease among 20,536 patients in the MRC/BHF heart protection study
od: Emberson, J, i dr.
Izdano: (2005)

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.
od: Collins, R, i dr.
Izdano: (2003)

MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomised placebo-controlled trial
od: Collins, R, i dr.
Izdano: (2002)

N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study.
od: Emberson, JR, i dr.
Izdano: (2007)

Need for large scale randomised evidence about lowering LDL cholesterol in people with diabetes mellitus: MRC/BHF heart protection study and other major trials.
od: Armitage, J, i dr.
Izdano: (2000)

Lipoprotein(a) genetic variants associated with coronary and peripheral vascular disease but not with stroke risk in the Heart Protection Study.
od: Hopewell, J, i dr.
Izdano: (2011)

Lipoprotein(a) Genetic Variants Associated With Risk of Atherothrombotic Disease in 14,465 Participants From the Heart Protection Study
od: Hopewell, J, i dr.
Izdano: (2010)

No Impact of KIF6 Genotype on Vascular Risk or Statin Benefit in the Heart Protection Study
od: Hopewell, J, i dr.
Izdano: (2009)

Genetic variation in lipid response to statin therapy in 18,705 participants in the heart protection study
od: Hopewell, J, i dr.
Izdano: (2011)

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.
od: Heart Protection Study Collaborative Group
Izdano: (2002)

Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study.
od: Hopewell, J, i dr.
Izdano: (2013)

No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study.
od: Hopewell, J, i dr.
Izdano: (2011)

Impact of apolipoprotein(a) isoform size on lipoprotein(a) lowering in the HPS2-THRIVE study
od: Parish, S, i dr.
Izdano: (2018)

Lipoprotein-associated phospholipase A(2) activity and mass in relation to vascular disease and nonvascular mortality
od: Parish, S, i dr.
Izdano: (2010)

The effects of vascular and nonvascular adverse events and of extended-release niacin with laropiprant on health and healthcare costs
od: Kent, S, i dr.
Izdano: (2016)

Impact of lipoprotein(a) levels and apolipoprotein(a) isoform size on risk of coronary heart disease
od: Hopewell, J, i dr.
Izdano: (2014)

Impact of lipoprotein(a) levels and apolipoprotein(a) isoform size on risk of coronary heart disease.
od: Hopewell, J, i dr.
Izdano: (2014)

No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study.
od: Hopewell, J, i dr.
Izdano: (2011)

Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions.
od: Collins, R, i dr.
Izdano: (2004)

The Impact of Genetic Variants Related to LDL-cholesterol on Risk of Ischemic Stroke and Coronary Heart Disease
od: Hopewell, J, i dr.
Izdano: (2012)

Assessing the impact sensitivity of explosives using the BHF-12A equipment
od: Rădeanu Cristian, i dr.
Izdano: (2020-01-01)

The MRC spine stabilization trial
od: Wilson-MacDonald, J, i dr.
Izdano: (2008)

Serious adverse effects of extended-release niacin/laropiprant: results from the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial
od: Haynes, R, i dr.
Izdano: (2019)

Assessment of Vascular Event Prevention and Cognitive Function Among Older Adults With Preexisting Vascular Disease or Diabetes: A Secondary Analysis of 3 Randomized Clinical Trials
od: Offer, A, i dr.
Izdano: (2019)

Association of Apolipoprotein(a) Isoforms With Coronary Heart Disease is Mediated Through Plasma Lipoprotein(a) Levels
od: Hopewell, J, i dr.
Izdano: (2010)

Lipids, lipoproteins and metabolites and risk of incident myocardial infarction and stroke subtypes
od: Holmes, M, i dr.
Izdano: (2017)

MRC2020: improvements to Ximdisp and the MRC image-processing programs
od: J. M. Short, i dr.
Izdano: (2023-09-01)

Failure Investigation of Blank Holder Force (BHF) Control in The Outside Bracket For Front Seat
od: Rofan Yulian Romansyah, i dr.
Izdano: (2023-06-01)

Environmental and genetic risk factors for myopathy in Chinese participants from HPS2-THRIVE
od: Hopewell, J, i dr.
Izdano: (2012)

Turkish Heart Study: lipids, lipoproteins, and apolipoproteins.
od: R W Mahley, i dr.
Izdano: (1995-04-01)

C-reactive protein in the Heart Protection Study - Authors' reply
od: Emberson, J, i dr.
Izdano: (2011)

Novel Size‐Based High‐Density Lipoprotein Subspecies and Incident Vascular Events
od: Austin Deets, i dr.
Izdano: (2023-11-01)

Heart Protection Study - Reply
od: Collins, R, i dr.
Izdano: (2003)

New analyses of Heart Protection Study - Reply
od: Collins, R, i dr.
Izdano: (2004)